Research Article

Interplay of T Helper 17 Cells with CD4⁺CD25⁰FOXP³⁺ Tregs in Regulation of Allergic Asthma in Pediatric Patients

Amit Agarwal, Meenu Singh, B. P. Chatterjee, Anil Chauhan, and Anuradha Chakraborti

1 Advanced Pediatric Centre, Post Graduate Institute of Medical Education and Research, Sector 12, Chandigarh 160012, India
2 Department of Natural Science, West Bengal University of Technology, Kolkata 700064, India
3 Department of Experimental Medicine and Biotechnology, Post Graduate Institute of Medical Education and Research, Chandigarh 160012, India

Correspondence should be addressed to Meenu Singh; meenusingh4@gmail.com

Received 3 March 2014; Revised 6 May 2014; Accepted 11 May 2014; Published 4 June 2014

Academic Editor: Emmanuel Katsanis

Copyright © 2014 Amit Agarwal et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. There is evidence that Tregs are important to prevent allergic diseases like asthma but limited literature exists on role of TH₁⁷ cells in allergic diseases. Methods. Fifty children with asthma and respiratory allergy (study group) and twenty healthy children (control group) were recruited in this study. Total IgE levels and pulmonary function tests were assessed. The expression of Tregs and cytokines was determined by flow cytometry. Results. The average level of total IgE in study group (316.8 ± 189.8 IU/mL) was significantly higher than controls (50 ± 17.5 IU/mL, \( P < 0.0001 \)). The frequency of TH₁⁷ cells and culture supernatant level of IL-17 in study group (12.09 ± 8.67 pg/mL) was significantly higher than control group (2.01 ± 1.27 pg/mL, \( P < 0.001 \)). Alternatively, the frequency of FOXP³ expression was significantly lower in study group [(49.00 ± 13.47)%] than in control group [(95.91 ± 2.63)%] and CD4⁺CD25⁰FOXP³⁺ to CD4⁺CD25⁰ ratio was also significantly decreased in study group [(6.33 ± 2.18)%] compared to control group [(38.61 ± 11.04)%]. The total serum IgE level is negatively correlated with FOXP³ level (\( r = -0.5273 \), \( P < 0.0001 \)). The FOXP³ expression is negatively correlated with the IL-17 levels (\( r = -0.5631 \), \( P < 0.0001 \)) and IL-4 levels (\( r = -0.2836 \), \( P = 0.0460 \)).

Conclusions. Imbalance in TH₁⁷/Tregs, elevated IL-17, and IL-4 response and downregulation of FOXP³ were associated with allergic asthma.

1. Introduction

Asthma, characterized by TH₂ immune response, is a chronic inflammatory disorder, affecting children worldwide [1]. It is now universally accepted that TH₁⁰ cells play a critical role in amplifying asthma [2] whereas TH₁¹ cytokines prevent this allergic inflammation [3, 4]. In recent years, it has been shown that the manifestation of asthma in humans is beyond the control of TH₁ and TH₂ cells. Some studies have suggested that other T cell subsets like TH₁⁷ and Treg also play a role in regulating asthma [5]. Treg cells play a key role in the maintenance and tolerance of immune regulation [6] by suppression of TH₁, TH₂, TH₁⁷, and allergen specific IgE. They have also been found to suppress basophils, eosinophils, and mast cells but induce levels of specific IgG4 [7]. Different types of Treg cells are classified as natural and adaptive [8]. Natural Treg cells possess high levels of CD25 (CD25⁰) present on the surface of T cells and the expression of FOXP³ required for the generation and maintenance of their suppressive activity [6, 8, 9], FOXP³ appears to be a key marker for CD4⁺CD25⁺ T cells and is considered as a master switch for development and function of natural Treg cells [10–13]. Recent studies suggest that Treg cells adopt different mechanisms to suppress immune responses: directly via cell contact and indirectly via reducing the capacity of antigen presentation on antigen presenting cells [14] or via anti-inflammatory cytokines [15, 16]. Some studies have suggested that pulmonary CD4⁺CD25⁺ Tregs are impaired in pediatric asthma [17]. A new subset of CD4⁺ T cells, termed as TH₁⁷, produces IL-17 [18]. TH₁⁷ cells are now considered the key mediator in development of asthma [19]. TH₁⁷ cells enhance both neutrophilic and eosinophilic
airway inflammation in mouse model of asthma [20, 21]. T_{H1}17 cells play a key role in mice filling the gap between T_{H1}1 and T_{H1}2 by secreting IL-17A and IL-17F and also contributing to immunity against certain extracellular bacteria and fungi [22]. IL-17, a proinflammatory cytokine mainly derived from CD4\(^ T\) cells and also from monocytes, mast cells, macrophages, and neutrophils [23, 24], has been suggested in modulating various inflammatory diseases like asthma in humans [24–26]. T_{H1}1 and T_{H1}2 cells as well as T_{H1}17 differentiation are suppressed by Tregs [27]. However, Treg cells do not suppress T_{H1}7 cells in vitro [28, 29]. Recent evidence indicates that CD4\(^ +\)CD25\(^{high}\)FOXP3\(^^+\) Tregs and T\(_{H1}17\) cells play an important role in mediating asthma.

**Hypothesis.** The null hypothesis states that T regulatory cells do not play any role in bronchial asthma. We hypothesize that T regulatory cells play a protective role in asthma. T regulatory cells, which regulate the balance between T_{H1}1 and T_{H1}2 cells, are downregulated in cases of asthma and allergy.

## 2. Materials and Methods

### 2.1. Subjects

Fifty children with asthma (study group) and twenty healthy children (control group) who were matched for age (in months) (control (88.86 ± 38.67); study group, (85.95 ± 35.55)) attended the Advanced Pediatric Centre in Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, and were diagnosed as asthma and were recruited in this study with their informed consent. The sera of age and sex matched nonallergic patients were taken as controls. The Ethics Committee of PGIMER approved this study (Micro/2006/754/8th May 2006).

### 2.2. Methods

The diagnosis of asthma was made by clinical history, physical examination, FEV1 measurement, positive response to bronchodilators, positive skin prick test, and elevated total IgE. The asthma of all patients was under control with inhaled corticosteroids. Blood samples were collected for evaluation of T_{H1}1, T_{H1}2, and T_{H1}17 expression and T_{reg} cells.

### 2.3. Estimation of Total IgE

The total IgE of allergic patients was measured using PATHOZYME immunoglobulin E OD 417 kit. The absorbance was measured at 450 nm after addition of tetramethyl benzidine hydrochloride (TMB) substrate and dilute hydrochloric acid. The concentration of IgE is directly proportional to the color intensity of the test samples. This test was calibrated to WHO 2nd International Reference Preparation 75/502 (1981).

### 2.4. Sample Preparation

Five milliliters of heparinized blood was obtained from 20 healthy subjects and 50 asthmatic patients. For cytokine analysis, plasma was isolated from peripheral blood and stored at −80°C until it was used. Peripheral blood mononuclear cells (PBMC) were isolated from heparinized blood sample by density gradient centrifugation (250 g for 20 minutes at room temperature) using Histopaque (Sigma-Aldrich, Saint Louis, MO, USA).

### 2.5. Flow Cytometric Analysis

The serum levels of cytokines Th1 (IFN-γ), Th2 (IL-2, IL-4, IL-6, IL-10, IL-12, and IL-13), and Th17 (IL-17) were assessed using BD CBA flex set. Tests were performed according to manufacturer’s instructions (BD Cytometric Bead Array, San Diego, CA). The analysis was carried out using flow cytometry (FACSCanto (Becton Dickinson, Mountain View, CA, USA) with FACS Diva Software).

For analysis of Treg cells, the buffy coat (lymphocytes and monocytes) was separated. The cell pellet washed with PBS (Phosphate Buffer Saline) was centrifugated at 200 g for 15 minutes. PBMCs were cultured in a petri dish containing 5% CO₂ at 37°C for one and half hour. Surface phenotyping (CD4 and CD25) of the cells (peripheral blood lymphocytes) and intracellular phenotyping (FOXP3) were performed by staining, paraformaldehyde fixation, and permeabilization according to the manufacturer’s instructions (BD biosciences San Diego, CA). PBMCs were determined using forward and side scatter properties based on size and granularity by FACSCanto (Becton Dickinson, Mountain View, CA, USA) with FACS Diva Software. The following mAbs (BD biosciences) were used: APC antihuman CD4, PE-Cy antihuman CD25, and PE antihuman FOXP3. To correct nonspecific binding, matched isotype controls were used.

### 2.6. Statistical Analysis

Data were analyzed with SPSS (v16.0; SPSS Inc, Chicago, IL, USA) and Graphpad prism (v5.0; Graphpad software Inc, Le Jolla, CA, USA). The mean values and their internal differentiation with standard deviations were calculated. The spearman’s r rank correlation coefficients were used to evaluate relationship between variables. When assessing the flow cytometric data, Student’s t-test was used. P values <0.05 were considered statistically significant.

## 3. Results

Total IgE and FEV1 levels were tested in all children diagnosed with asthma. The difference between IgE levels in study and control group was analyzed using Graphpad Prism software. The nonparametric Student’s t-test was applied between study group and control group for total IgE level. The average level of total IgE in study group (316.8 ± 189.8 IU/mL, range 80–720 IU/mL) was significantly higher than in control group (50.3 ± 17.5 IU/mL, range 10–80 IU/mL, P < 0.001) (Figure 1(a)). FEV1 (% predicted) was significantly lower in study group (75.36 ± 14.45) compared to control group (102.3 ± 8.97, P < 0.0001) (Table 1). Total serum IgE and FEV1 levels were also analyzed for their correlation studies. This was analyzed using Spearman’s correlation coefficient in study group only. There was a negative correlation between total IgE and FEV1% levels (r = −0.4820, P = 0.0004) (Figure 1(b)).

### 3.1. Expression of Cytokines in Asthmatic Children

Levels of cytokines IL-2, IL-4, IL-6, IL-10, IL-12, IL-13, IFN-γ, and IL-17 in sera were expressed as mean ± standard deviation. The average level of IL-17 expression in study group (12.09 ± 8.67 pg/mL) was significantly higher than the corresponding values in control group (2.01 ± 1.27 pg/mL, P < 0.0001)
Study group Control group

**Total IgE (IU/mL) (mean ± SD)**
- Study group: 316.8 ± 189.8
- Control group: 50.3 ± 17.5

**FEV1 (%) (mean ± SD)**
- Study group: 75.36 ± 14.45
- Control group: 102.3 ± 8.97

*Figure 1:* (a) Total IgE level in study and control group. (b) Correlation between total IgE and % FEV1 levels in study group.

(Figure 2(a)) but values of IFN-γ were significantly lower in study group (12.08 ± 8.67 pg/mL) compared to control group (21.00 ± 7.53 pg/mL, *P* = 0.009) (Figure 2(b)). No significant difference was observed between study and control group for other cytokines (IL-2: 20.78 ± 9.22 pg/mL versus 18.93 ± 13.73 pg/mL, *P* = 0.51; IL-4: 21.88 ± 10.35 pg/mL versus 19.79 ± 12.38 pg/mL, *P* = 0.47; IL-6: 18.17 ± 10.49 pg/mL versus 15.11 ± 9.79 pg/mL, *P* = 0.08; IL-10: 22.82 ± 19.16 pg/mL versus 18.62 ± 5.31 pg/mL, *P* = 0.35; IL-12: 17.58 ± 9.27 pg/mL versus 16.94 ± 11.00, *P* = 0.52; IL-13: 34.55 ± 17.51 pg/mL versus 29.39 ± 10.12 pg/mL, *P* = 0.40) (Table 2).

The Student’s *t*-test was done to analyze IL-17 in control and study group. The results depict a significant difference between the two groups (*P* < 0.0001). Similarly, there was also significant difference between study group and control group for IFN-γ (*P* = 0.009).

Flow cytometric analysis of FOXP3 was performed in CD4+CD25+ cells for both control (*n* = 20) (Figure 3) and study group (*n* = 50) (Figure 4). The percentages of FOXP3 expression were significantly lower in study group ((49.00 ± 13.47)%)) than in control group ((95.91 ± 2.63)%), *P* < 0.0001) (Figure 5).

A further analysis was done to calculate CD4+CD25+ FOXP3⁺ to CD4+CD25⁺ ratio, which was significantly decreased in study group ((6.33 ± 2.18)%) compared to control group ((38.61 ± 11.04)%, *P* < 0.0001) (Figure 6).

**Table 1: Patients characteristics.**

|                      | Study group | Control group |
|----------------------|-------------|---------------|
| Total subjects       | 50          | 20            |
| Age (months (mean ± SD)) | 88.86 ± 38.67 | 85.95 ± 35.55 |
| Male; n (%)          | 40 (80%)    | 14 (70%)      |
| Total IgE (IU/mL)    | 316.8 ± 189.8 | 50.3 ± 17.5   |
| (mean ± SD)          |             |               |
| FEV1 (%) (mean ± SD) | 75.36 ± 14.45 | 102.3 ± 8.97  |

*Table 2: Cytokine expression in study and control group.*

**IL-17 concentration (pg/mL)**

Figure 2: (a) IL-17 and (b) IFN-γ expression in study and control.
Figure 3: The expression level of CD4+CD25+ and FOXP3 was examined by flow cytometry in control group. (a) Representation plots of CD4+CD25+ cells (b) and FOXP3 expression in control group.

Table 2: Cytokine expression in study group with SPT positive for one or more food allergen and control group.

| Cytokines   | Study group* N = 50 | Control group* N = 20 | P value |
|-------------|---------------------|-----------------------|---------|
| IFN-γ       | 12.46 ± 8.89        | 21.00 ± 7.53          | P = 0.009 |
| IL-2        | 18.93 ± 13.73       | 20.78 ± 9.22          | P = 0.51  |
| IL-4        | 19.79 ± 12.38       | 21.88 ± 10.35         | P = 0.47  |
| IL-6        | 15.11 ± 9.79        | 18.17 ± 10.49         | P = 0.08  |
| IL-10       | 22.82 ± 19.16       | 18.62 ± 5.31          | P = 0.35  |
| IL-12p7     | 16.94 ± 11.00       | 17.58 ± 9.27          | P = 0.52  |
| IL-13       | 34.55 ± 17.51       | 29.39 ± 10.12         | P = 0.40  |
| IL-17A      | 12.09 ± 8.67        | 2.01 ± 1.27           | P < 0.0001|

*Values are expressed in Mean ± SD pg/mL.

3.2. Correlation Analysis

3.2.1. Relationship of Total IgE and FOXP3 Expression. There was a significant negative correlation between %FOXP3/CD4+CD25high and total IgE level (r = −0.5273, P < 0.0001) (Figure 7).

3.2.2. Interaction between FOXP3 Expression and Level of IL-17 and IL-4. FOXP3 percentage and IL-17 level had a significant inverse correlation with each other (r = −0.5631, P < 0.0001) (Figure 8(a)). There was also a significant correlation between %FOXP3 and IL-4 (r = −0.2836, P = 0.0460) (Figure 8(b)).

4. Discussion

The present work demonstrates the relationship between TH17 and Treg cells. It is universally accepted that total IgE level is directly correlated with allergy and asthma. In our study, the average level of total IgE was significantly higher in children with bronchial asthma compared to healthy subjects. On the basis of available studies, we had hypothesized that Treg cells would be associated with lower levels of allergy markers such as IgE and TH2 cytokines. Most studies of Treg activity come from immunotherapy studies in allergic diseases [30]. FOXP3 transcription factor has been shown as a key regulator for development of Treg cells and is expressed by these cells [10, 11, 31]. In our study, we found that FOXP3 level is significantly lower in study group compared to control group. Furthermore, there was a negative correlation between total IgE and FOXP3 expression. In this study, we also demonstrated a TH17/Treg cytokine profile in study group. Studies have suggested that asthma is associated with chronic and recurrent inflammation [32]. TH2 cells are associated directly with inflammation whereas TH17 cells behave primarily as proinflammatory markers [33]. Studies suggested
that transcription factors and cytokines are involved in generation, differentiation, and expansion of TH₁₇ cells. The interaction between TH₁₇ cells and Tregs in various inflammatory diseases needs to be further defined [34]. The knowledge of suppressive activity of Treg cells in atopic disease is still contradictory and limited. This study supports the notion that function of Tregs is altered or impaired in allergic patients compared to healthy individuals [13, 17, 35–40]. However, there are some studies that have shown results going the opposite way [41–43]. These alterations may be related to different allergic diseases, different environmental influences, and differences in methodology for identification of cell markers that are used in proper identification of Tregs. In our study, we found significantly higher IL-17 level in
asthmatic patients compared to controls. Previous studies showed that IL-17 is elevated in sputum samples of patients with asthma compared to healthy controls [44–46]. Another study showed that patients with asthma had elevated IL-17 levels in serum compared with control subjects [47]. It has been suggested that IL-17 plays an important role in inflammatory and autoimmune diseases [48]. In patients with asthma, IL-17 level was significantly increased and T cell population was skewed toward T\textsubscript{H}17 phenotype. Thus, there is a correlation of increase in IL-17 levels in patients with asthma coupled with a significant decrease in transcription factor FOXP3 Treg level when compared to controls.

We could not find a study in children with asthma reporting the relationship of T\textsubscript{H}17 with Treg response in the milieu of T\textsubscript{H}2 activity. These results show that there is a correlation between FOXP3 and IL-17 level and also a functional imbalance in T\textsubscript{H}17/Treg in children with asthma. In this study, we demonstrated that IL-17 and FOXP3 are reciprocally interconnected with each other. It has already been shown that CD4\textsuperscript{+}CD25\textsuperscript{+}FOXP3\textsuperscript{+} play a protective role in autoimmune disease [12]. We found that the suppressive activity of CD4\textsuperscript{+}CD25\textsuperscript{high} T cells was variable, which is already reported in previous studies [49, 50]. FOXP3 transcription factor plays a key role in regulation and development of CD4\textsuperscript{+}CD25\textsuperscript{+} T cells and is expressed by these cells [10, 11, 31]. Our study also shows that there is a significant negative correlation between IL-4 and FOXP3.

In conclusion, the present study demonstrates that there is an imbalance between T\textsubscript{H}17 and Tregs associated with asthma, which may play a potential role in development of asthma. Our study also shows inverse correlation between IL-17 and FOXP3. Future studies are needed to clarify these findings.

**Abbreviations**

FOXP3: Forkhead box P3  
IL: Interleukin  
Treg: Regulatory T cell  
FACS: Fluorescence-activated cell sorting  
IgE: Immunoglobin E  
FEV1: Forced expiratory volume 1  
HRP: Horseradish peroxidase  
mAbs: Monoclonal antibodies  
PBMC: Peripheral blood mononuclear cell.
Conflict of Interests
The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgment
The research is supported by the funds from Indian Council of Medical Research, India (Grant no. 62/1/2006-BMS).

References

[1] E. von Mutius, “Influences in allergy: epidemiology and the environment,” Journal of Allergy and Clinical Immunology, vol. 113, no. 3, pp. 373–380, 2004.

[2] H. Y. Kim, R. H. Dekruyff, and D. T. Umetu, “The many paths to asthma: phenotype shaped by innate and adaptive immunity,” Nature Immunology, vol. 11, no. 7, pp. 577–584, 2010.

[3] M. Larché, D. S. Robinson, and A. B. Kay, “The role of T lymphocytes in the pathogenesis of asthma,” Journal of Allergy and Clinical Immunology, vol. 113, no. 3, pp. 450–463, 2003.

[4] S. Baraldo, K. L. Oliani, G. Turato, R. Zuin, and M. Saetta, “The role of lymphocytes in the pathogenesis of asthma and COPD,” Current Medicinal Chemistry, vol. 14, no. 21, pp. 2250–2256, 2007.

[5] A. Mubeccel, “Immunetolerance in allergy,” Current Opinion in Allergy and Clinical Immunology, vol. 11, no. 3, pp. 253–257, 2007.

[6] J. M. Kim, J. P. Rasmussen, and A. Y. Rudensky, “Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice,” Nature Immunology, vol. 8, no. 2, pp. 191–197, 2007.

[7] R. H. Wilson, G. S. Whitehead, H. Nakano, M. E. Free, J. K. Kolls, and D. N. Cook, “Allergic sensitization through the airway primes TH17-dependent neutrophilia and airway hyper-responsiveness,” American Journal of Respiratory and Critical Care Medicine, vol. 180, no. 8, pp. 720–730, 2009.

[8] S. Fowler and F. Powrie, “Control of immune pathology by IL-10-secreting regulatory T cells,” Springer Seminars in Immunopathology, vol. 21, no. 3, pp. 287–294, 1999.

[9] F. Powrie, J. Carlino, M. W. Leach, S. Mauze, and R. L. Coffman, “A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4+ T cells,” The Journal of Experimental Medicine, vol. 183, no. 6, pp. 2669–2674, 1996.

[10] S. A. Newhouse, D. T. Umetu, and A. H. Karlsson, “Quantitative and functional impairment of pulmonary CD4+CD25hi regulatory T cells in pediatric asthma,” Journal of Allergy and Clinical Immunology, vol. 119, no. 5, pp. 1258–1266, 2007.

[11] A. Peck and E. D. Mellins, “Plasticity of T-cell phenotype and function: the T helper type 17 example,” Immunology, vol. 129, no. 2, pp. 147–153, 2010.

[12] A. Awasthi and V. K. Kuchroo, “Th17 cells: from precursors to players in inflammation and infection,” International Immunology, vol. 21, no. 5, pp. 489–498, 2009.

[13] H. Wakashin, K. Hirose, Y. Maezawa et al., “IL-23 and Th17 cells enhance Th2-cell-mediated eosinophilic airway inflammation in mice,” American Journal of Respiratory and Critical Care Medicine, vol. 178, no. 10, pp. 1023–1032, 2008.

[14] H. Powrie, J. Carlino, M. W. Leach, S. Mauze, and R. L. Coffman, “A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4+ T cells,” The Journal of Experimental Medicine, vol. 183, no. 6, pp. 2669–2674, 1996.

[15] S. Fowler and F. Powrie, “Control of immune pathology by IL-10-secreting regulatory T cells,” Springer Seminars in Immunopathology, vol. 21, no. 3, pp. 287–294, 1999.

[16] F. Powrie, J. Carlino, M. W. Leach, S. Mauze, and R. L. Coffman, “A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4+ T cells,” The Journal of Experimental Medicine, vol. 183, no. 6, pp. 2669–2674, 1996.

[17] D. Hartl, B. Koller, A. T. Mehlike et al., “Quantitative and functional impairment of pulmonary CD4+CD25hi regulatory T cells in pediatric asthma,” Journal of Allergy and Clinical Immunology, vol. 119, no. 5, pp. 1258–1266, 2007.

[18] A. Peck and E. D. Mellins, “Plasticity of T-cell phenotype and function: the T helper type 17 example,” Immunology, vol. 129, no. 2, pp. 147–153, 2010.

[19] A. Awasthi and V. K. Kuchroo, “Th17 cells: from precursors to players in inflammation and infection,” International Immunology, vol. 21, no. 5, pp. 489–498, 2009.

[20] H. Wakashin, K. Hirose, Y. Maezawa et al., “IL-23 and Th17 cells enhance Th2-cell-mediated eosinophilic airway inflammation in mice,” American Journal of Respiratory and Critical Care Medicine, vol. 178, no. 10, pp. 1023–1032, 2008.

[21] R. H. Wilson, G. S. Whitehead, H. Nakano, M. E. Free, J. K. Kolls, and D. N. Cook, “Allergic sensitization through the airway primes TH17-dependent neutrophilia and airway hyper-responsiveness,” American Journal of Respiratory and Critical Care Medicine, vol. 180, no. 8, pp. 720–730, 2009.

[22] M. M. Curtis and S. S. Way, “Interleukin-17 in host defence against bacterial, mycobacterial and fungal pathogens,” Immunology, vol. 126, no. 2, pp. 177–185, 2009.

[23] T. Korn, E. Bettelli, M. Oukka, and V. K. Kuchroo, “IL-17 and Th17 cells,” Annual Review of Immunology, vol. 27, pp. 485–517, 2009.

[24] S. Fujino, A. Andoh, S. Bamba et al., “Increased expression of interleukin 17 in inflammatory bowel disease,” Gut, vol. 52, no. 1, pp. 65–70, 2003.

[25] C. E. Jones and K. Chan, “Interleukin-17 stimulates the expression of interleukin-8, growth-related oncogene-α, and granulocyte-colony-stimulating factor by human airway epithelial cells,” American Journal of Respiratory Cell and Molecular Biology, vol. 26, no. 6, pp. 748–753, 2002.

[26] S. Ivanov and A. Lindén, “Interleukin-17 as a drug target in human disease,” Trends in Pharmacological Sciences, vol. 30, no. 2, pp. 95–103, 2009.

[27] J. M. Kim, J. P. Rasmussen, and A. Y. Rudensky, “Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice,” Nature Immunology, vol. 8, no. 2, pp. 191–197, 2007.

[28] F. Annunziato, L. Cosmi, V. Santarlasci et al., “Phenotypic and functional features of human Th17 cells,” Journal of Experimental Medicine, vol. 204, no. 8, pp. 1849–1861, 2007.

[29] R. A. O’Connor, K. H. Malpass, and S. M. Anderson, “The inflamed central nervous system drives the activation and rapid proliferation of Foxp3+ regulatory T cells,” Journal of Immunology, vol. 179, no. 2, pp. 958–966, 2007.

[30] A. Mubeccel, “Immune tolerance in allergy,” Current Opinion in Immunology, vol. 21, no. 6, pp. 700–707, 2009.

[31] M. R. Walker, D. J. Kasprowicz, V. H. Gersuk et al., “Induction of Foxp3 and acquisition of T regulatory activity by stimulated human CD4+CD25+ T cells,” Journal of Clinical Investigation, vol. 112, no. 9, pp. 1437–1443, 2003.
[32] D. M. Murphy and P. M. O’Byrne, “Recent advances in the pathophysiology of asthma,” *Chest*, vol. 137, no. 6, pp. 1417–1426, 2010.

[33] M. Veldhoen and B. Stockinger, “TGF-β1, a “Jack of all trades”: the link with pro-inflammatory IL-17-producing T cells,” *Trends in Immunology*, vol. 27, no. 8, pp. 358–361, 2006.

[34] J. Mai, H. Wang, and X.-F. Yang, “Th17 cells interplay with Foxp3+ Tregs in regulation of inflammation and autoimmunity,” *Frontiers in Bioscience*, vol. 15, no. 3, pp. 986–1006, 2010.

[35] T. A. Chatila, “Role of regulatory T cells in human diseases,” *Journal of Allergy and Clinical Immunology*, vol. 116, no. 5, pp. 949–960, 2005.

[36] M. Akdis, K. Blaser, and C. A. Akdis, “T regulatory cells in allergy: novel concepts in the pathogenesis, prevention, and treatment of allergic diseases,” *Journal of Allergy and Clinical Immunology*, vol. 116, no. 5, pp. 961–969, 2005.

[37] M. A. Gavin, J. P. Rasmussen, J. D. Fontenot et al., “Foxp3-dependent programme of regulatory T-cell differentiation,” *Nature*, vol. 445, no. 7129, pp. 771–775, 2007.

[38] T. Jartti, K. A. Burmeister, C. M. Seroogy et al., “Association between CD4+CD25high T cells and atopy in children,” *Journal of Allergy and Clinical Immunology*, vol. 120, no. 1, pp. 177–183, 2007.

[39] W. G. Shreffler, N. Wanich, M. Moloney, A. Nowak-Wegrzyn, and H. A. Sampson, “Association of allergen-specific regulatory T cells with the onset of clinical tolerance to milk protein,” *Journal of Allergy and Clinical Immunology*, vol. 123, no. 1, pp. 43.e7–52.e7, 2009.

[40] M. Smith, M. R. Tourigny, P. Noakes, C. A. Thornton, M. K. Tulic, and S. L. Prescott, “Children with egg allergy have evidence of reduced neonatal CD4+CD25+CD127lo/- regulatory T cell function,” *Journal of Allergy and Clinical Immunology*, vol. 121, no. 6, pp. 1460.e7–1466.e7, 2008.

[41] M. M. Tiemessen, E. van Hoffen, A. C. Knulst, J.-A. van der Zee, E. F. Knol, and L. S. Taams, “CD4+CD25+ regulatory T cells are not functionally impaired in adult patients with IgE-mediated cow’s milk allergy,” *Journal of Allergy and Clinical Immunology*, vol. 110, no. 6, pp. 934–936, 2002.

[42] L.-S. Ou, E. Goleva, C. Hall, and D. Y. M. Leung, “T regulatory cells in atopic dermatitis and subversion of their activity by superantigens,” *Journal of Allergy and Clinical Immunology*, vol. 113, no. 4, pp. 756–763, 2004.

[43] A. L. Taylor, J. Hale, B. J. Hales, J. A. Dunstan, W. R. Thomas, and S. L. Prescott, “FOXP3 mRNA expression at 6 months of age is higher in infants who develop atopic dermatitis, but is not affected by giving probiotics from birth,” *Pediatric Allergy and Immunology*, vol. 18, no. 1, pp. 10–19, 2007.

[44] S. Molet, Q. Hamid, F. Davoine et al., “IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines,” *Journal of Allergy and Clinical Immunology*, vol. 108, no. 3, pp. 430–438, 2001L.

[45] A. Barczyk, W. Pierzcha, and E. Sozańska, “Interleukin-17 in sputum correlates with airway hyperresponsiveness to methacholine,” *Respiratory Medicine*, vol. 97, no. 6, pp. 726–733, 2003.

[46] D. M. A. Bullens, E. Truyen, L. Coteur et al., “IL-17 mRNA in sputum of asthmatic patients: linking T cell driven inflammation and granulocytic influx?” *Respiratory Research*, vol. 7, article 135, 2006.

[47] C. K. Wong, C. Y. Ho, F. W. S. Ko et al., “Proinflammatory cytokines (IL-17, IL-6, IL-18 and IL-12) and Th cytokines (IFN-γ, IL-4, IL-10 and IL-13) in patients with allergic asthma,” *Clinical and Experimental Immunology*, vol. 125, no. 2, pp. 177–183, 2001.